-+ 0.00%
-+ 0.00%
-+ 0.00%

Mira Pharmaceuticals submits FDA Phase 2a trial protocol for Ketamir-2 in chemotherapy-induced neuropathy

PUBT·06/17/2026 12:02:17
Listen to the news
Mira Pharmaceuticals submits FDA Phase 2a trial protocol for Ketamir-2 in chemotherapy-induced neuropathy
  • Mira Pharmaceuticals submitted an FDA Phase 2a trial protocol for Ketamir-2 to treat chemotherapy-induced peripheral neuropathy.
  • Planned randomized, double-blind, placebo-controlled crossover study tests 300 mg, 600 mg doses in patients with persistent moderate-to-severe pain.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-028992), on June 17, 2026, and is solely responsible for the information contained therein.